Mesoblast FY EPS $(0.11) Beats $(0.57) Estimate, Sales $7.50M Miss $7.97M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mesoblast (NASDAQ:MESO) reported Q4 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.57) by 80.7%. However, the company's quarterly sales of $7.50 million missed the analyst consensus estimate of $7.97 million by 5.90%. This represents a 26.47% decrease over sales of $10.20 million from the same period last year.
August 31, 2023 | 6:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mesoblast's Q4 earnings beat estimates but sales missed, indicating mixed performance. The decrease in sales YoY could negatively impact investor sentiment.
While Mesoblast beat earnings estimates, the miss on sales and the significant YoY decrease could be a concern for investors, potentially leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100